Compare ADMA Biologics Inc (ADMA) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Western Alliance Bancorporation — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Western Alliance Bancorporation trades at $78.78 (market cap $9.01B). The key difference: Western Alliance Bancorporation is far larger — about 4.2× ADMA Biologics Inc's market cap, and Western Alliance Bancorporation pays a 2.04% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WAL | |
|---|---|---|
Market Cap | $2.13B | $9.01B |
Sector | Health | Financials |
52-Week High | $20.38 | $96.08 |
52-Week Low | $7.60 | $66.70 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Western Alliance Bancorporation (WAL) trades at $82.50, up 1.18% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with a P/E of 9.6 and net income margin of 25.63%. Recent news highlights business expansion and industry recognition, including a #1 ranking in Arizona by Forbes.
The outlook is positive, driven by earnings momentum and a consensus price target of $90.67, offering ~10% upside. Risks include negative operating cash flow and high interest expenses, but strong institutional buy ratings and recent corporate developments support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
